Merck ends study of cholesterol drug

Merck & Co. has halted a study of an experimental drug it had touted as key to energizing its sagging cholesterol franchise, barely three weeks after U.S. regulators refused to allow sales of the drug.

Comments

• Find It

• Recently Written

  • test post
  • Dietary Adherence Associated with Better Glucose Control in Children with Type 1 Diabetes
  • Children becoming more vulnerable to diabetes
  • Topanga Girl Describes Losing Sight; Motrin Blamed
  • The Underlying Molecular Mechanism For Hypertension, Insulin…
  • Rapid Tests for Drug-resistant TB to be Available in Developing Countries
  • Two-Drug Treatment Didn’t Improve Cardiac Arrest Survival Rates
  • Many Sunscreens Ineffective, Group Says
  • Canada Takes More Action to Protect Human Health and the Environment Under World Leading Chemicals Management Plan
  • Aradigm Corporation Reports Successful Top-line Phase 2 Data with…

• Categories

  • News

• Monthly Archives

  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007

• Blogroll

  • Attorney Daily » Drug Injury News
  • Dangerous Drug Lawyer
  • Drugs.com - Pharma News
  • FDA MedWatch
  • Health Canada RSS
  • Lawyers and Settlements :: Drugs/Medical
  • Medication News

• Admin

  • Register
  • Log in
  • XHTML

Copyright © 2008 Drug Injury News